Trial Profile
A 2-Part, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CAT-2054 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Jul 2022
Price :
$35
*
At a glance
- Drugs CAT 2054 (Primary)
- Indications Hypercholesterolaemia
- Focus Adverse reactions
- Sponsors Astria Therapeutics; Catabasis Pharmaceuticals
- 16 May 2016 Data will be presented at the National Lipid Association 2016 Scientific Sessions, according to a Catabasis Pharmaceuticals media release.
- 17 Aug 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 13 Aug 2015 Results published in a Catabasis media release.